SIRIC ILIAD shares its research progress with its partners | SIRIC Review 2018-2022
The SIRIC ILIAD Partners Committee met on Monday 17 October 2022 to present the results of the 5 years of
Nuclear medicine in Nantes at the SNMMI 2022 Meeting
A film on the Nantes nuclear medicine cluster is being shown throughout the SNMMI international congress being held in Vancouver
In 2022, the CRCINA evolves and becomes the CRCI²NA
In January 2022, at the end of its five-year mandate, the CRCINA (Centre de Recherche en Cancérologie et Immunologie Nantes
The SIRIC ILIAD teams are proud to be partners of the RHU OPERANDI
At the beginning of 2022, the ThARGET programme teams of SIRIC ILIAD are now partners in the Hospital-University Health Research
Cancer research: The importance of SIRICs recognised by the scientific committee of INCa
Following the mid-term evaluation of the SIRICs (SIte de Recherche Intégrée sur le Cancer), the scientific committee of the French
IMRAM industrial chair: a new stage in the collaboration between Nantes University Hospital and Siemens
Following the installation of new Siemens imaging equipment at the Nantes University Hospital last May, the public-private partnership between Siemens
ISI NucMed 2022 – June 27-29th 2022, Nantes
Interdisciplinary School In Nuclear Medicine (ISI NucMed) 2022 Arronax organises the Interdisciplinary School (ISI) In Nuclear Medicine (NucMed) from 27
SIRIC ILIAD’s research on breast cancer in video
Video : Introduction to SIRIC ILIAD’s research work on breast cancer The SIRIC ILIAD Nantes-Angers (Integrated Cancer Research Site) was
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer : The OPALESCENCE study, a collaborative research
Nantes research on astatine in the spotlight
Nantes research on astatine in the spotlight Astatine (At) is the rarest chemical element on Earth, and its 211 isotope
